Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 360 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
2021
Polyzos, S. A., Anastasilakis A. D., Efstathiadou Z. A., Yavropoulou M. P., & Makras P. (2021).  Postmenopausal osteoporosis coexisting with other metabolic diseases: Treatment considerations.. Maturitas. 147, 19-25.
Boziki, M., Polyzos S. A., Papaefthymiou A., Doulberis M., Bakirtzis C., Sintila S-A., et al. (2021).  Potential impact of Helicobacter pylori-related metabolic syndrome and Galectin-3 on liver, chronic kidney and brain disorders.. Metabolism. 154736.
Kountouras, J., Papaefthymiou A., Polyzos S. A., & Doulberis M. (2021).  A potential impact of Helicobacter pylori-related sarcopenia on severity of portal hypertension.. Liver Int.
Polyzos, S. A., Kechagias S., & Tsochatzis E. A. (2021).  Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations.. Aliment Pharmacol Ther.
Papaefthymiou, A., Christodoulidis G., Koffas A., Doulberis M., Polyzos S. A., Manolakis A., et al. (2021).  Role of autophagy in gastric carcinogenesis.. World J Gastrointest Oncol. 13(10), 1244-1262.
Makri, E. S., Goulas A., & Polyzos S. A. (2021).  Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.. Eur J Pharmacol. 907, 174272.
Boziki, M., Grigoriadis N., Papaefthymiou A., Doulberis M., Polyzos S. A., Gavalas E., et al. (2021).  The trimebutine effect on Helicobacter pylori-related gastrointestinal tract and brain disorders: A hypothesis.. Neurochem Int. 144, 104938.
Anastasilakis, A. D., Polyzos S. A., Kitridis D., Makras P., Yavropoulou M. P., Palermo A., et al. (2021).  Ιrisin levels in postmenopausal women with an incident hip fracture.. Endocrine. 73(3), 719-722.
2020
Doulberis, M., Srivastava S., Polyzos S. A., Kountouras J., Papaefthymiou A., Klukowska-Rötzler J., et al. (2020).  Active Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients.. J Clin Med. 9(4), 
Doulberis, M., Kotronis G., Gialamprinou D., Polyzos S. A., Papaefthymiou A., Katsinelos P., et al. (2020).  Alzheimer's disease and gastrointestinal microbiota; impact of infection involvement.. Int J Neurosci. 1-13.
Doulberis, M., Papaefthymiou A., Polyzos S. A., Bargiotas P., Liatsos C., Srivastava D. Shiva, et al. (2020).  Association between Active Infection and Glaucoma: A Systematic Review and Meta-Analysis.. Microorganisms. 8(6), 
Anastasilakis, A. D., Polyzos S. A., Yavropoulou M. P., & Makras P. (2020).  Combination and sequential treatment in women with postmenopausal osteoporosis.. Expert Opin Pharmacother. 21(4), 477-490.
Polyzos, S. A., Kang E. Seok, Tsochatzis E. A., Kechagias S., Ekstedt M., Xanthakos S., et al. (2020).  Commentary: Nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name.. Metabolism. 113, 154413.
Makri, E., Kita M., Goulas A., Papaioannidou P., Efstathiadou Z. A., Adamidou F., et al. (2020).  Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus.. Diabetes Metab Syndr. 14(6), 1913-1919.
Polyzos, S. A., Kang E. Seok, Boutari C., Rhee E-J., & Mantzoros C. S. (2020).  Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.. Metabolism. 154203.
Polyzos, S. A., Kountouras J., Goulas A., Papakonstantinou E., & Papaioannidou P. (2020).  Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity.. Hepatobiliary Surg Nutr. 9(1), 73-76.
Polyzos, S. A., & Kountouras J. (2020).  Enriched MACK-3 following CHAI and MACK-3 for the noninvasive diagnosis of nonalcoholic steatohepatitis.. Ann Hepatol. 19(5), 579-580.
Kountouras, J., Papaefthymiou A., Polyzos S. A., Zavos C., & Doulberis M. (2020).  Erratum to: Letter to the editor re: Li et al. (2020), 'The potential role of bacteria in pancreatic cancer: A systematic review'.. Carcinogenesis.
Kountouras, J., Papaefthymiou A., Gavalas E., Polyzos S. A., Boziki M., Kyriakou P., et al. (2020).  Helicobacter pylori infection as a potential risk factor for multiple sclerosis.. Med Hypotheses. 143, 110135.
Doulberis, M., Papaefthymiou A., Polyzos S. A., Kotronis G., Gialamprinou D., Tzitiridou-Chatzopoulou M., et al. (2020).  Helicobacter pylori, Sleeve Gastrectomy, and Gastroesophageal Reflux Disease: Is There a Relation?. Obes Surg.
Polyzos, S. A., Papaefthymiou A., Doulberis M., Katsinelos P., & Kountouras J. (2020).  Homocysteine in nonalcoholic steatohepatitis: seemingly a paradox revisited.. J Gastrointestin Liver Dis. 29(2), 270-271.
Kountouras, J., Doulberis M., Papaefthymiou A., & Polyzos S. A. (2020).  Impact of Helicobacter pylori-linked metabolic syndrome on non-alcoholic fatty liver disease and its connected atrial fibrillation risk.. Liver Int.
Papaefthymiou, A., Doulberis M., Polyzos S. A., Katsinelos P., Liatsos C., Koffas A., et al. (2020).  Letter: Helicobacter pylori in proton pump inhibitor-associated biliary disease.. Aliment Pharmacol Ther. 51(2), 313-314.
Papaefthymiou, A., Doulberis M., Polyzos S. A., Katsinelos P., & Kountouras J. (2020).  Letter: Helicobacter pylori infection and its role in oesophageal adenocarcinoma.. Aliment Pharmacol Ther. 51(11), 1215-1216.
Polyzos, S. A., & Mantzoros C. S. (2020).  Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD).. Metabolism. 154318.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές